百奥泰(688177.SH):BAT4406F注射液获得药物临床试验批准通知书

智通财经
Jul 21, 2025

智通财经APP讯,百奥泰(688177.SH)发布公告,公司于近日收到国家药品监督管理局(简称“国家药监局”)核准签发的关于公司在研药品BAT4406F注射液新增微小病变肾病/局灶节段性肾小球硬化适应症的《药物临床试验批准通知书》。

BAT4406F为公司开发的新一代糖基优化的全人源抗CD20抗体,特异性与B细胞及前体细胞表面的CD20分子结合,通过抗体Fc段,在补体、NK自然杀伤性细胞、吞噬细胞等存在的情况下,诱发ADCC、CDC(补体依赖的细胞毒性)等生物学效应从而达到清除B细胞的目的。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10